Tradewinds LLC. Makes New $695,000 Investment in CVRx, Inc. (NASDAQ:CVRX)

Tradewinds LLC. bought a new position in shares of CVRx, Inc. (NASDAQ:CVRX) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 54,836 shares of the company’s stock, valued at approximately $695,000. Tradewinds LLC. owned 0.23% of CVRx at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Calamos Advisors LLC acquired a new position in shares of CVRx in the 4th quarter valued at $134,000. XTX Topco Ltd purchased a new stake in CVRx during the 3rd quarter worth $150,000. Jane Street Group LLC increased its holdings in CVRx by 36.1% in the 3rd quarter. Jane Street Group LLC now owns 19,038 shares of the company’s stock valued at $168,000 after purchasing an additional 5,053 shares in the last quarter. Barclays PLC raised its position in CVRx by 312.5% in the third quarter. Barclays PLC now owns 19,067 shares of the company’s stock valued at $169,000 after purchasing an additional 14,445 shares during the period. Finally, Centiva Capital LP purchased a new stake in shares of CVRx in the third quarter worth about $178,000. 75.27% of the stock is owned by institutional investors and hedge funds.

CVRx Stock Down 2.1 %

NASDAQ:CVRX opened at $12.23 on Tuesday. CVRx, Inc. has a 52 week low of $6.40 and a 52 week high of $19.24. The firm has a market capitalization of $318.42 million, a PE ratio of -4.55 and a beta of 1.34. The company has a current ratio of 12.06, a quick ratio of 10.23 and a debt-to-equity ratio of 0.69. The stock has a 50 day moving average of $13.92 and a 200-day moving average of $12.88.

CVRx (NASDAQ:CVRX) last posted its earnings results on Tuesday, February 4th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.06). CVRx had a negative net margin of 116.91% and a negative return on equity of 93.06%. Analysts predict that CVRx, Inc. will post -1.91 EPS for the current year.

Wall Street Analyst Weigh In

CVRX has been the topic of a number of recent research reports. Canaccord Genuity Group boosted their target price on shares of CVRx from $22.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, February 5th. William Blair raised CVRx from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 14th. Craig Hallum increased their target price on CVRx from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Friday, January 17th. Finally, Piper Sandler increased their price objective on shares of CVRx from $16.00 to $20.00 and gave the company an “overweight” rating in a research note on Wednesday, February 5th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $17.83.

CVRx Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.